{"id":470547,"date":"2021-04-05T06:48:25","date_gmt":"2021-04-05T10:48:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470547"},"modified":"2021-04-05T06:48:25","modified_gmt":"2021-04-05T10:48:25","slug":"david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/","title":{"rendered":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund<\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fivericbio.com%2F&amp;esheet=52406209&amp;newsitemid=20210405005187&amp;lan=en-US&amp;anchor=IVERIC+bio%2C+Inc.&amp;index=1&amp;md5=7267825bb69f504ec3a89e43c71af65b\">IVERIC bio, Inc.<\/a> (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio\u2019s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric\u2019s Board of Directors since its founding. During Dr. Guyer\u2019s tenure he led the Company from its initial public offering to being a late-stage clinical company focused on the discovery and development of both therapeutic and gene therapy treatment options for retinal diseases. Dr. Guyer will rejoin SV Health Investors as a Venture Partner having previously been both a Venture Partner and Partner at SV.\n<\/p>\n<p>\n\u201cAs a co-founder, former Chief Executive Officer and most recently Executive Chair, David has been an integral part of Iveric Bio\u2019s leadership, a trusted advisor and visionary in retinal medicine, and I sincerely thank him for his hard work and significant contributions to the Company,\u201d stated Glenn P. Sblendorio, Chief Executive Officer and President of Iveric Bio. \u201cOn behalf of the entire Company, we are grateful to have had the opportunity to work closely with David over the years and we wish him continued success.\u201d\n<\/p>\n<p>\n&#8220;Iveric Bio&#8217;s strong management team has evolved to the point where there is no longer a need for an Executive Chair,\u201d stated Dr. Guyer. \u201cAfter more than 14 years on the Board, I feel that this is a good departure point such that I can return to my passion as a venture capitalist. I will rejoin SV Health Investors where I will be able to focus on new company generation and board service. I am very excited about Iveric&#8217;s Phase 3 program of Zimura<sup>\u00ae<\/sup> for the treatment of geographic atrophy secondary to age-related macular degeneration and look forward to continuing to serve the Company as a Senior Advisor.&#8221;\n<\/p>\n<p>\n\u201cDavid\u2019s contributions to Iveric Bio have been significant,\u201d stated Axel Bolte, Member of the Board of Iveric Bio. \u201cAfter having worked with David throughout most of his tenure with the Company, it will be hard to imagine board meetings without David\u2019s presence and clinical insights. We are grateful that David agreed to the Board\u2019s request that he serve as a senior advisor so that we can continue to work with him even if in a different role.\u201d\n<\/p>\n<p><b>About Iveric Bio<br \/>\n<br \/><\/b>Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ivericbio.com&amp;esheet=52406209&amp;newsitemid=20210405005187&amp;lan=en-US&amp;anchor=www.ivericbio.com&amp;index=2&amp;md5=7d0ece6511855ac6770fde9d24bd7cb8\">www.ivericbio.com<\/a>.\n<\/p>\n<p><b><i>Forward-looking Statements<br \/>\n<br \/><\/i><\/b><i>Any statements in this press release about the Company\u2019s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company\u2019s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend\u201d, \u201cgoal,\u201d \u201cmay\u201d, \u201cmight,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions. In this press release, the Company\u2019s forward looking statements include statements about the future development of its product candidates and Dr. Guyer\u2019s future role as senior advisor to the Company. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company\u2019s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, reliance on university collaborators and other third parties, establishment of manufacturing capabilities, expectations for regulatory matters, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the \u201cRisk Factors\u201d section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company\u2019s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.<\/i><\/p>\n<p><b>ISEE-G<\/b><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210405005187\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210405005187\/en\/<\/a><\/span><\/p>\n<p><b>Investor \/ Media Contact:<br \/>\n<\/b><br \/>Iveric Bio<br \/>\n<br \/>Kathy Galante, 212-845-8231<br \/>\n<br \/>Vice President, Investor Relations and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kathy.galante@ivericbio.com\">kathy.galante@ivericbio.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>SmithSolve<br \/>\n<br \/>Alex Van Rees, 973-442-1555 ext. 111<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:alex.vanrees@smithsolve.com\">alex.vanrees@smithsolve.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical Optical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210405005187\/en\/718702\/3\/IVERIC_bio.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund NEW YORK&#8211;(BUSINESS WIRE)&#8211;IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio\u2019s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric\u2019s Board of Directors since its founding. During Dr. Guyer\u2019s tenure he led the Company from its initial public offering to being a late-stage clinical company focused on the discovery and development of both therapeutic and gene therapy treatment options for retinal diseases. Dr. Guyer will rejoin SV Health Investors as a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470547","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund NEW YORK&#8211;(BUSINESS WIRE)&#8211;IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio\u2019s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric\u2019s Board of Directors since its founding. During Dr. Guyer\u2019s tenure he led the Company from its initial public offering to being a late-stage clinical company focused on the discovery and development of both therapeutic and gene therapy treatment options for retinal diseases. Dr. Guyer will rejoin SV Health Investors as a &hellip; Continue reading &quot;David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T10:48:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund\",\"datePublished\":\"2021-04-05T10:48:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/\"},\"wordCount\":850,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/\",\"name\":\"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-05T10:48:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/","og_locale":"en_US","og_type":"article","og_title":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk","og_description":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund NEW YORK&#8211;(BUSINESS WIRE)&#8211;IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio\u2019s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric\u2019s Board of Directors since its founding. During Dr. Guyer\u2019s tenure he led the Company from its initial public offering to being a late-stage clinical company focused on the discovery and development of both therapeutic and gene therapy treatment options for retinal diseases. Dr. Guyer will rejoin SV Health Investors as a &hellip; Continue reading \"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T10:48:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund","datePublished":"2021-04-05T10:48:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/"},"wordCount":850,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/","name":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-05T10:48:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210405005187r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470547"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470547\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}